首页 | 本学科首页   官方微博 | 高级检索  
     


A Bayesian dose‐finding design for drug combination clinical trials based on the logistic model
Authors:Marie‐Karelle Riviere  Ying Yuan  Frédéric Dubois  Sarah Zohar
Affiliation:1. INSERM, UMRS 1138, Equipe 22, Centre de Recherche des Cordeliers, Université Paris 5, Université Paris 6, , Paris, France;2. IRIS (Institut de Recherches Internationales Servier), , Suresnes, France;3. Department of Biostatistics, The University of Texas MD Anderson Cancer Center, , Houston, TX, 77030 USA
Abstract:In early phase dose‐finding cancer studies, the objective is to determine the maximum tolerated dose, defined as the highest dose with an acceptable dose‐limiting toxicity rate. Finding this dose for drug‐combination trials is complicated because of drug–drug interactions, and many trial designs have been proposed to address this issue. These designs rely on complicated statistical models that typically are not familiar to clinicians, and are rarely used in practice. The aim of this paper is to propose a Bayesian dose‐finding design for drug combination trials based on standard logistic regression. Under the proposed design, we continuously update the posterior estimates of the model parameters to make the decisions of dose assignment and early stopping. Simulation studies show that the proposed design is competitive and outperforms some existing designs. We also extend our design to handle delayed toxicities. Copyright © 2014 John Wiley & Sons, Ltd.
Keywords:Bayesian inference  dose finding  drug combination  oncology  phase I trial
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号